Amelioration and treatment of brain disorder resulting from fetal growth retardation using pluripotent stem cells

A technology for pluripotent stem cells and growth retardation, applied in the field of cell preparations to achieve the effect of reducing brain damage

Pending Publication Date: 2020-03-06
NAGOYA UNIVERSITY +3
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there have been no cases where the expected therapeutic effect was obtained using Muse cells in the improvement and / or treatment of brain damage accompanied by fetal growth retardation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Amelioration and treatment of brain disorder resulting from fetal growth retardation using pluripotent stem cells
  • Amelioration and treatment of brain disorder resulting from fetal growth retardation using pluripotent stem cells
  • Amelioration and treatment of brain disorder resulting from fetal growth retardation using pluripotent stem cells

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0084] (2) Preparation and use of cell preparations and pharmaceutical compositions

[0085]As far as the cell preparation and pharmaceutical composition of the present invention are concerned, there is no limitation, and the Muse cells obtained in the above (1) or the cell population containing Muse cells can be suspended in physiological saline, an appropriate buffer (such as phosphate-buffered saline) get in. In this case, when the number of Muse cells isolated from the tissue of oneself or another individual is small, the cells can be cultured and proliferated until a predetermined cell concentration is obtained before administration. It should be noted that, as reported (International Publication No. WO2011 / 007900 pamphlet), Muse cells do not become tumors, so even if they contain cells recovered from living tissue in an undifferentiated state, there is a possibility of canceration. Sex is also low and is safe. In addition, the recovered Muse cells can be cultured in a ...

Embodiment 1

[0103] Example 1: Production of fetal growth retardation model rats and administration of Muse cells

[0104] The experimental protocol involving experimental animals used in this study was approved by the Committee on Animal Experiments, Faculty of Medicine, Nagoya University. Pregnant SD rats were obtained from Japan SLC Co., Ltd. (Shizuoka Prefecture, Japan), put into cages where they could freely ingest food and water, and raised under a 12-hour light-dark cycle. Animal rooms and experimental spaces were maintained at 23°C at all times.

[0105] A vasoconstrictor (AC) (inner diameter: 0.45 mm or 0.40 mm) was installed at four positions in the uterine artery of a female rat on the 17th day of pregnancy to cause chronic ischemia of the fetus to create an intrauterine growth model. Rat pups produced by this female were used as models of fetal growth retardation. It should be noted that the fetal growth retardation of the rats born was determined by confirming the following ...

Embodiment 2

[0107] Example 2: Evaluation of brain function improvement (after one month after birth) using AC (0.45mm)

[0108] (1) Negative geotaxis test

[0109] Improvement of behavioral disorder caused by brain damage accompanying fetal growth retardation by transplantation of Muse cells or the like was investigated by a negative geotaxis test. Fetal growth retardation model rats (hereinafter sometimes simply referred to as "rats") are placed head-down on a 30-degree inclined board, and the time (seconds) until the rat responds and climbs up is measured, and the time is used to Evaluate the effect of each treatment. The number of rats in each group was n=31 in the sham operation group, n=18 in the blank control group, n=19 in the Muse cell-administered group, and n=18 in the non-Muse cell group. In this test, rats were 8 to 11 days old, and the test was carried out once a day for 4 consecutive days. The negative geotaxis test of each group is shown in Figure 1A . The vertical axi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The purpose of the present invention is to provide a novel medical application of pluripotent stem cells (muse cells) in regeneration medicine. The present invention provides a cell preparation and apharmaceutical composition which are for amelioration and treatment of brain disorders resulting from fetal growth retardation, such as abnormal motor quality or abnormal neurological development, andwhich contain SSEA-3 positive pluripotent stem cells isolated from a mesenchymal tissue from a live body or cultured mesenchymal cells. It is assumed that this cell preparation is based on a mechanism where muse cells that are administered to objects having the disorders are engrafted on an impaired brain tissue, thereby ameliorating or treating the disorders.

Description

technical field [0001] The present invention relates to cell preparations in regenerative medicine. More specifically, it relates to a cell preparation containing pluripotent stem cells, which is effective for the treatment of brain damage accompanied by fetal growth retardation, and a new treatment method. [0002] Background of the invention [0003] Fetal growth retardation (FGR, or intrauterine growth restriction: IUGR) occurs due to various reasons. FGR caused by pregnancy-induced hypertension onset in the second trimester is associated with chronic hypoxemia, circulatory failure, and nutrition through the placenta. The combined effect such as adverse effects is the cause of neurological sequelae such as mental retardation and cognitive impairment, and its treatment method has not yet been established. Currently, fetal growth retardation is found in about 8 to 10% of all pregnancies, and is confirmed in about 18% of perinatal deaths and about 31% of fetal deaths. In ad...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/545A61P25/14A61P25/28C12N5/0775
CPCA61K35/545A61P25/14A61P25/28A01K2227/105A01K2207/30A01K2267/035C12N5/0606C12N5/0623C12N5/0618C12N5/0619C12N5/0663C12N5/0668C12N5/0662C12N5/0665C12N5/0667C12N5/0607
Inventor 佐藤义朗北濑悠磨清水忍水野正明早川昌弘出泽真理辻雅弘
Owner NAGOYA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap